• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » ReWalk Robotics to acquire anti-gravity tech provider AlterG for $19M

ReWalk Robotics to acquire anti-gravity tech provider AlterG for $19M

August 9, 2023 By Sean Whooley

AlterG anti-gravity treadmill acquired by ReWalk Robotics (1)
The AlterG anti-gravity treadmill. ReWalk Robotics acquired AlterG for an upfront price of $19 million. [Image from AlterG]
ReWalk Robotics (Nasdaq:RWLK) announced that it executed an agreement to acquire AlterG, an anti-gravity system provider.

The deal includes a purchase price of approximately $19 million at closing. ReWalk expects to close the deal on Aug. 11, with closing contingent upon the satisfaction of customary closing conditions. Additional cash earnouts may be paid based upon a percentage of AlterG’s future revenue growth in the next two.

ReWalk aims to strengthen its long-term financial position and path to profitability through this deal. In fiscal 2022, AlterG generated $20 million in revenue and recorded a positive operating profit.

“This transaction is truly transformative for ReWalk and is a milestone in our long-term strategy for growth from both our existing portfolio of products and from synergistic acquisitions,” said Larry Jasinski, CEO of ReWalk. “We believe this transaction will leverage our combined market presence from both businesses and, by creating sales and support efficiencies across all product lines, accelerate our path to profitability.

“Through this transaction, we believe we will create a formidable commercial infrastructure to support multiple additional products across the continuum of care from the clinic to the home.”

More about AlterG

AlterG provides anti-gravity systems for use in physical and neurological rehabilitation. The transaction adds its current and future product lines to ReWalk’s existing portfolio of neurorehabilitation products. ReWalk also expects it to substantially expand its customer-facing capabilities and advance future growth opportunities.

The anti-gravity systems developed by AlterG use patented, NASA-derived differential air pressure technology. They reduce the effects of gravity, allowing people to move in new ways with finely calibrated support and reduced pain. AlterG designed its technology to enable users to recover mobility, improve wellness and enhance physical performance.

“AlterG and ReWalk share a common vision of combining synergistic industry-leading products into a world-class portfolio, which leverages our collective strengths,” said Charles Remsberg, CEO of AlterG. “This transaction instantly creates the scale to fund next-generation enhancements to our existing products and to pursue other innovative and commercial rehabilitation technologies that further strengthen our relationships with our customers as a key resource for innovative solutions in neurological and physical rehabilitation.”

Following the transaction, Remsberg will join the executive team at ReWalk in the role of chief sales officer.

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Neurological, News Well, Orthopedics, Prosthetics, Spine, Surgical Robotics Tagged With: AlterG, ReWalk Robotics

More recent news

  • Paradromics’ first study participant uses BCI for real-time speech
  • Medtronic hires former Recor CEO to run interventional cardiology group
  • Abbott wins FDA approval for Aveir VR Mini ventricular leadless pacemaker
  • Dexcom CFO to expand into COO role
  • Powerful Medical announces FDA De Novo nod for AI ECG and other extra medtech news

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy